摘要
肠促胰素已成为治疗2型糖尿病的热点。胰高血糖素样肽-1具有促进胰岛素合成和分泌、抑制胰高血糖素分泌、促进胰岛β细胞增殖的生理功能。此外,胰高血糖素样肽-1还具有延缓胃排空、抑制食欲和调节脂肪代谢等功能。艾塞那肽和利拉鲁肽是目前临床应用较多的胰高血糖素样肽-1类似物,临床研究证实其能有效降低血糖、糖化血红蛋白水平及体重指数且无低血糖反应,为2型糖尿病患者治疗带来了新的希望。胰高血糖素样肽-1类似物也存在一定的不良反应,其长期安全性有待进一步观察研究。
Incretin has become a hot spot to treat type 2 diabetes. Glucagon-like peptide-1 can promote insulin synthesis and secretion,inhibition of glucagon secretion, and promote pancreatic β cell proliferation. In addition, glucagon-like peptide-1 also has delayed gastric emptying, suppress appetite and regulate fat metabolism and so on. Exenatide and liraglutide are the clinical application of glucagon-like peptide-1 analogues, clinical studies confirmed that they can effectively reduce blood glucose,glycosylated hemoglobin level and body mass index and no hypoglycemia,which has brought new hope for type 2 diabetes. Glucagon-like peptide-1 analogues also has some ad- verse reactions, further observation and study of its lonz-term safetv needs to be.
出处
《海峡药学》
2014年第7期88-90,共3页
Strait Pharmaceutical Journal
